Based on the Viatris Inc stock forecast from 5 analysts, the average analyst target price for Viatris Inc is USD 11.75 over the next 12 months. Viatris Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Viatris Inc is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Viatris Inc’s stock price was USD 7.61. Viatris Inc’s stock price has changed by -12.63% over the past week, -21.14% over the past month and -35.23% over the last year.
No recent analyst target price found for Viatris Inc
No recent average analyst rating found for Viatris Inc
Company Overview Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Read Less
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater Chi...Read More
Frequently Asked Questions About Viatris Inc (VTRS) Stock
Based on ratings from 5 analysts Viatris Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 2 sell and 2 hold ratings.
VTRS stock's dividend yield is 5.14%.
Our analysis grades VTRS stock's dividend yield at A+. This means that VTRS stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this VTRS may be a good dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for VTRS is USD 11.75 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 9.
VTRS stock's Price/Earning ratio is 225.00.
Our analysis grades VTRS stock's Price / Earning ratio at F. This means that VTRS stock's Price/Earning ratio is above 93% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this VTRS may be a overvalued for its sector.
The last closing price of VTRS's stock was USD 7.61.
The most recent market capitalization for VTRS is USD 11.15B.
Based on targets from 5 analysts, the average taret price for VTRS is projected at USD 11.75 over the next 12 months.
This means that VTRS's stock price may go up by +59.65% over the next 12 months.
We can't find any ETFs which contains Viatris Inc's stock.
As per our most recent records Viatris Inc has 32,000 Employees.
Viatris Inc's registered address is Robert J. Coury Global Center, Canonsburg, PA, United States, 15317.
You can get more information about it from Viatris Inc's website at https://www.viatris.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Viatris Inc (VTRS) Stock
Based on ratings from 5 analysts Viatris Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, 2 sell and 2 hold ratings.
VTRS stock's dividend yield is 5.14%.
Our analysis grades VTRS stock's dividend yield at A+. This means that VTRS stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this VTRS may be a good dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for VTRS is USD 11.75 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 9.
VTRS stock's Price/Earning ratio is 225.00.
Our analysis grades VTRS stock's Price / Earning ratio at F. This means that VTRS stock's Price/Earning ratio is above 93% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this VTRS may be a overvalued for its sector.
The last closing price of VTRS's stock was USD 7.61.
The most recent market capitalization for VTRS is USD 11.15B.
Based on targets from 5 analysts, the average taret price for VTRS is projected at USD 11.75 over the next 12 months.
This means that VTRS's stock price may go up by +59.65% over the next 12 months.
We can't find any ETFs which contains Viatris Inc's stock.
As per our most recent records Viatris Inc has 32,000 Employees.
Viatris Inc's registered address is Robert J. Coury Global Center, Canonsburg, PA, United States, 15317.
You can get more information about it from Viatris Inc's website at https://www.viatris.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VTRS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
